Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer

NEW YORK–()–Regulatory News:

(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), a
clinical-stage biopharmaceutical company focused on developing
immunotherapies based on gene-edited allogeneic CAR T-cells (UCART),
announced today the appointment of Prof. Stéphane Depil, MD, PhD, to the
role of Senior Vice President Research & Development and Chief Medical
Officer. Prof. Depil’s responsibilities include bringing Cellectis’
product candidates to clinical-stage development, strategic and
operational management of all therapeutic activities, and supervising
research and development projects for the Company. Stéphane Depil will
keep academic and research activities as adjunct Professor at Léon
Bérard Cancer Center & University Claude Bernard Lyon 1, France.

“Stéphane Depil’s deep medical, academic, and clinical regulatory
oncology experience – specifically in R&D for all phases within the
pharmaceutical, biotechnology, and clinical research spaces – will be
invaluable as he leads Cellectis’ strategy and promotes awareness of the
breakthrough work that we are doing as a leader and innovator in the
gene-editing field,” said Dr. André Choulika, Cellectis CEO. “His
strategic alliance-building, collaboration skills, understanding of the
global environment with oncological clinical research, and firsthand
experience running a pharma company all add a great degree of ability
and depth to our leadership team. This will be tremendously advantageous
as Cellectis continues its efforts to cure cancer with our off-the-shelf
gene-edited CAR T-cell product candidates.”

Prof. Depil is a board-certified physician in hematology, with over 15
years of experience in oncology clinical development, both in hospital /
university and pharmaceutical companies. Prior to joining the Léon
Bérard Cancer Center & Cancer Research Center of Lyon, France as Medical
Director of the Cancer Immunotherapy Program, he served as Chief
Executive Officer at Netris Pharma, where he was responsible for the
management of an oncology startup and preclinical development of a
first-in-class monoclonal antibody in Phase I. Prior to Netris, Stéphane
Depil worked at Servier for 8 years in a variety of roles, including
Director of Oncology Research and Development, where he managed 20
programs: 5 in the clinic, 7 at late preclinical stages, and 8 at early
preclinical stages. He also directly supervised over 100 licensing

“As we are at a transformative moment in history with CAR T-cell
therapy, Cellectis is harnessing the power of gene editing to improve
patients’ lives through the allogeneic approach,” added Prof. Depil. “As
such, Cellectis is well-positioned to make its mark with the Company’s
unique pioneering approach, and I look forward to joining the team at
this pivotal time. This is an unprecedented era of biopharmaceutical
innovation to develop next-generation therapeutics that will transform
patient care as we know it today.”

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing – built on its flagship TALEN® technology and
pioneering electroporation system PulseAgile – Cellectis uses the power
of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.


This press release contains “forward-looking” statements that are based
on our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risks factors that may affect company
business and financial performance, is included in filings Cellectis
makes with the Security Exchange Commission from time to time and its
financial reports. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.